Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19991409 | 1.00 | IDH1 (0.64) | IDH1 | |
| SCHEMBL20560022 | 0.90 | IDH1 (0.66) | IDH1 | |
| SCHEMBL19991307 | 0.90 | IDH1 (0.74) | IDH1 | |
| SCHEMBL20560020 | 0.90 | IDH1 (0.66) | IDH1 | |
| SCHEMBL17603794 | 0.90 | IDH1 (0.74) | IDH1 | |
| SCHEMBL17604000 | 0.89 | IDH1 (0.75) | IDH1 | |
| SCHEMBL19991313 | 0.89 | IDH1 (0.75) | IDH1 | |
| SCHEMBL17603337 | 0.87 | IDH1 (0.57) | IDH1 | |
| SCHEMBL17601597 | 0.86 | IDH1 (0.82) | IDH1 | |
| SCHEMBL17603984 | 0.84 | IDH1 (0.54) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3201185-B1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | claimed |
| US-20180086733-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-03-29 | — | — | US | claimed |
| US-9771349-B2 | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | claimed |
| EP-3201185-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-08-09 | — | — | EP | claimed |
| WO-2016044787-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | claimed |
| US-20160083367-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | claimed |
| US-20190135781-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10253015-B2 | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3201185-B1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180327382-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180086733-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9771349-B2 | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| EP-3201185-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016044787-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083367-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135781-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH2, IDH3A | IDH1 1/4885 |
| US-10253015-B2 | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | IDH1 1/4885 |
| US-20160083367-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | IDH1 1/4885 |
| US-20180327382-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | IDH1 1/4885 |
| US-20180086733-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | IDH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.